188 related articles for article (PubMed ID: 23992223)
1. Successful eradication of inhibitor in a patient with severe haemophilia B and anaphylaxis to factor IX concentrates: is there a role for Rituximab and desensitization therapy?
Gamerman S; Singh AM; Makhija M; Sharathkumar A
Haemophilia; 2013 Nov; 19(6):e382-5. PubMed ID: 23992223
[No Abstract] [Full Text] [Related]
2. Autoimmune haemophilia in a teenager.
Batra S; Sharathkumar A; Glaubach T; Gamerman S; Green D
Haemophilia; 2013 Nov; 19(6):e386-8. PubMed ID: 23992250
[No Abstract] [Full Text] [Related]
3. Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX.
Barnes C; Davis A; Furmedge J; Egan B; Donnan L; Monagle P
Haemophilia; 2010 Sep; 16(5):840-1. PubMed ID: 20546030
[No Abstract] [Full Text] [Related]
4. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate.
Chuansumrit A; Moonsup Y; Sirachainan N; Benjaponpitak S; Suebsangad A; Wongwerawattanakoon P
Blood Coagul Fibrinolysis; 2008 Apr; 19(3):208-11. PubMed ID: 18388500
[TBL] [Abstract][Full Text] [Related]
5. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis.
Alexander S; Hopewell S; Hunter S; Chouksey A
J Pediatr Hematol Oncol; 2008 Jan; 30(1):93-5. PubMed ID: 18176193
[TBL] [Abstract][Full Text] [Related]
6. A rare case of an acquired inhibitor to factor IX.
Krishnamurthy P; Hawche C; Evans G; Winter M
Haemophilia; 2011 Jul; 17(4):712-3. PubMed ID: 21371188
[No Abstract] [Full Text] [Related]
7. Successful treatment of a patient with acquired haemophilia A with a combination of a low-dose rituximab and recombinant human FVIIa.
Xu Y; Zhang X; Zhao Y; Zhao L; Qiu H; Wu D
Haemophilia; 2013 Mar; 19(2):e95-6. PubMed ID: 23231056
[No Abstract] [Full Text] [Related]
8. Efficacy of rituximab in acquired factor XIII inhibitor after arterial rFVIIa-induced thrombosis.
Ngo Sack F; Galinat H; Egreteau PY; Mollard LM; Fortin H; Berthou C; Abgrall JF; Pan-Petesch B
Haemophilia; 2013 Mar; 19(2):e93-4. PubMed ID: 23205641
[No Abstract] [Full Text] [Related]
9. Major orthopaedic surgery for a haemophilia patient with inhibitors using a new bypassing agent.
Takedani H; Hirose J; Minamoto F; Kubota M; Kinkawa J; Noguchi M
Haemophilia; 2016 Sep; 22(5):e459-61. PubMed ID: 27456673
[No Abstract] [Full Text] [Related]
10. Inhibitor eradication with rituximab in haemophilia: where do we stand?
Franchini M; Mannucci PM
Br J Haematol; 2014 Jun; 165(5):600-8. PubMed ID: 24628543
[TBL] [Abstract][Full Text] [Related]
11. Eradication of factor IX neutralizing and anaphylactic inhibitors in a patient with severe haemophilia B using cyclophosphamide immune suppression and factor IX desensitization.
Greenmyer JR; Grindeland CJ; Kobrinsky NL
Haemophilia; 2020 Mar; 26(2):e51-e54. PubMed ID: 31961035
[No Abstract] [Full Text] [Related]
12. Identical but different: haemophilia B in monozygotic twins with inhibitor in one brother and subsequent successful immune tolerance induction.
Ranta S; Verbruggen B; Wikström A; Mäkipernaa A
Haemophilia; 2012 Jul; 18(4):e349-51. PubMed ID: 22631443
[No Abstract] [Full Text] [Related]
13. [Acquired haemophilia: From registers' data to therapeutic recommendations].
Lévesque H
Rev Med Interne; 2013 Jan; 34(1):1-3. PubMed ID: 22998977
[No Abstract] [Full Text] [Related]
14. Management of difficult-to-treat inhibitor patients.
Giangrande PL; Escobar MA
Haemophilia; 2010 May; 16 Suppl 3():52-7. PubMed ID: 20586803
[TBL] [Abstract][Full Text] [Related]
15. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
Shirahata A; Fukutake K; Takamatsu J; Shima M; Hanabusa H; Mugishima H; Amano K; Takedani H; Tamashima S; Matsushita T; Tawa A; Tanaka I; Higasa S; Kosaka Y; Fujii T; Sakai M; Migita M; Kawakami K; Ohashi Y; Saito H
Haemophilia; 2013 Nov; 19(6):853-60. PubMed ID: 23738888
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
[No Abstract] [Full Text] [Related]
17. Continuous infusion of coagulation factor concentrates during intensive treatment.
Holme PA; Tjønnfjord GE; Batorova A
Haemophilia; 2018 Jan; 24(1):24-32. PubMed ID: 28873263
[TBL] [Abstract][Full Text] [Related]
18. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
Astermark J; Rocino A; Von Depka M; Van Den Berg HM; Gringeri A; Mantovani LG; Morado M; Garrido RP; Schiavoni M; Villar A; Windyga J;
Haemophilia; 2007 Jan; 13(1):38-45. PubMed ID: 17212723
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
Mathias M; Khair K; Hann I; Liesner R
Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
